Zydus Receives USFDA EIR for Baddi Facility
Zydus Lifesciences has announced that the company has received the Establishment Inspection Report (EIR) from the U.S. Food and Drugs Administration (USFDA) for an inspection conducted at its manufacturing facility located at Baddi.
The inspection was conducted from 4th to 13th August 2025, and the company received four observations in August. The EIR has classified the facility as Voluntary Action Indicated (VAI), and the USFDA has concluded this inspection as closed.
Zydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
No additional quotes available.
Author's summary: Zydus Lifesciences receives USFDA EIR for Baddi facility.